BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

423 related articles for article (PubMed ID: 23486334)

  • 1. Choline PET or PET/CT and biochemical relapse of prostate cancer: a systematic review and meta-analysis.
    Evangelista L; Zattoni F; Guttilla A; Saladini G; Zattoni F; Colletti PM; Rubello D
    Clin Nucl Med; 2013 May; 38(5):305-14. PubMed ID: 23486334
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utility of choline positron emission tomography/computed tomography for lymph node involvement identification in intermediate- to high-risk prostate cancer: a systematic literature review and meta-analysis.
    Evangelista L; Guttilla A; Zattoni F; Muzzio PC; Zattoni F
    Eur Urol; 2013 Jun; 63(6):1040-8. PubMed ID: 23036576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PET/CT with (11)C-choline for evaluation of prostate cancer patients with biochemical recurrence: meta-analysis and critical review of available data.
    Fanti S; Minozzi S; Castellucci P; Balduzzi S; Herrmann K; Krause BJ; Oyen W; Chiti A
    Eur J Nucl Med Mol Imaging; 2016 Jan; 43(1):55-69. PubMed ID: 26450693
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early biochemical relapse after radical prostatectomy: which prostate cancer patients may benefit from a restaging 11C-Choline PET/CT scan before salvage radiation therapy?
    Castellucci P; Ceci F; Graziani T; Schiavina R; Brunocilla E; Mazzarotto R; Pettinato C; Celli M; Lodi F; Fanti S
    J Nucl Med; 2014 Sep; 55(9):1424-9. PubMed ID: 24935990
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [18F]fluoromethylcholine (FCH) positron emission tomography/computed tomography (PET/CT) for lymph node staging of prostate cancer: a prospective study of 210 patients.
    Poulsen MH; Bouchelouche K; Høilund-Carlsen PF; Petersen H; Gerke O; Steffansen SI; Marcussen N; Svolgaard N; Vach W; Geertsen U; Walter S
    BJU Int; 2012 Dec; 110(11):1666-71. PubMed ID: 22520686
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radiolabeled choline PET/CT before salvage lymphadenectomy dissection: a systematic review and meta-analysis.
    Evangelista L; Zattoni F; Karnes RJ; Novara G; Lowe V
    Nucl Med Commun; 2016 Dec; 37(12):1223-1231. PubMed ID: 27551835
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of 18F-choline PET/CT in prostate cancer patients with biochemical recurrence: influence of androgen deprivation therapy and correlation with PSA kinetics.
    Beheshti M; Haim S; Zakavi R; Steinmair M; Waldenberger P; Kunit T; Nader M; Langsteger W; Loidl W
    J Nucl Med; 2013 Jun; 54(6):833-40. PubMed ID: 23559588
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 11C-choline PET/CT detects the site of relapse in the majority of prostate cancer patients showing biochemical recurrence after EBRT.
    Ceci F; Castellucci P; Graziani T; Schiavina R; Brunocilla E; Mazzarotto R; Ntreta M; Lodi F; Martorana G; Fanti S
    Eur J Nucl Med Mol Imaging; 2014 May; 41(5):878-86. PubMed ID: 24346416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. (11)C-Choline PET/CT for restaging prostate cancer. Results from 4,426 scans in a single-centre patient series.
    Graziani T; Ceci F; Castellucci P; Polverari G; Lima GM; Lodi F; Morganti AG; Ardizzoni A; Schiavina R; Fanti S
    Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):1971-9. PubMed ID: 27277279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of 11C-choline and 18F-fluorocholine positron emission tomography (PET) and PET/CT in prostate cancer: a systematic review and meta-analysis.
    Umbehr MH; Müntener M; Hany T; Sulser T; Bachmann LM
    Eur Urol; 2013 Jul; 64(1):106-17. PubMed ID: 23628493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical utility of (18)F-fluorocholine positron-emission tomography/computed tomography (PET/CT) in biochemical relapse of prostate cancer after radical treatment: results of a multicentre study.
    Rodado-Marina S; Coronado-Poggio M; García-Vicente AM; García-Garzón JR; Alonso-Farto JC; de la Jara AC; Maldonado-Suárez A; Rodríguez-Fernández A
    BJU Int; 2015 Jun; 115(6):874-83. PubMed ID: 25307619
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 11C-choline PET/CT predicts prostate cancer-specific survival in patients with biochemical failure during androgen-deprivation therapy.
    Giovacchini G; Picchio M; Garcia-Parra R; Briganti A; Abdollah F; Gianolli L; Schindler C; Montorsi F; Messa C; Fazio F
    J Nucl Med; 2014 Feb; 55(2):233-41. PubMed ID: 24408897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Meta-analysis of (11)C-choline and (18)F-choline PET/CT for management of patients with prostate cancer.
    von Eyben FE; Kairemo K
    Nucl Med Commun; 2014 Mar; 35(3):221-30. PubMed ID: 24240194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of choline positron emission tomography/computed tomography in the management of patients with prostate-specific antigen progression after radical treatment of prostate cancer.
    Picchio M; Briganti A; Fanti S; Heidenreich A; Krause BJ; Messa C; Montorsi F; Reske SN; Thalmann GN
    Eur Urol; 2011 Jan; 59(1):51-60. PubMed ID: 20869161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of recurrent prostate cancer after radical prostatectomy: comparison of 11C-choline PET/CT with pelvic multiparametric MR imaging with endorectal coil.
    Kitajima K; Murphy RC; Nathan MA; Froemming AT; Hagen CE; Takahashi N; Kawashima A
    J Nucl Med; 2014 Feb; 55(2):223-32. PubMed ID: 24434294
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histological verification of 11C-choline-positron emission/computed tomography-positive lymph nodes in patients with biochemical failure after treatment for localized prostate cancer.
    Schilling D; Schlemmer HP; Wagner PH; Böttcher P; Merseburger AS; Aschoff P; Bares R; Pfannenberg C; Ganswindt U; Corvin S; Stenzl A
    BJU Int; 2008 Aug; 102(4):446-51. PubMed ID: 18410442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does Choline PET/CT Change the Management of Prostate Cancer Patients With Biochemical Failure?
    Goldstein J; Even-Sapir E; Ben-Haim S; Saad A; Spieler B; Davidson T; Berger R; Weiss I; Appel S; Lawrence YR; Symon Z
    Am J Clin Oncol; 2017 Jun; 40(3):256-259. PubMed ID: 25319322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of total PSA, PSA doubling time and PSA velocity on detection rates of 11C-Choline positron emission tomography in recurrent prostate cancer.
    Rybalov M; Breeuwsma AJ; Leliveld AM; Pruim J; Dierckx RA; de Jong IJ
    World J Urol; 2013 Apr; 31(2):319-23. PubMed ID: 22814886
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of lymph-node metastases with integrated [11C]choline PET/CT in patients with PSA failure after radical retropubic prostatectomy: results confirmed by open pelvic-retroperitoneal lymphadenectomy.
    Scattoni V; Picchio M; Suardi N; Messa C; Freschi M; Roscigno M; Da Pozzo L; Bocciardi A; Rigatti P; Fazio F
    Eur Urol; 2007 Aug; 52(2):423-9. PubMed ID: 17397992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 18F-FACBC compared with 11C-choline PET/CT in patients with biochemical relapse after radical prostatectomy: a prospective study in 28 patients.
    Nanni C; Schiavina R; Brunocilla E; Borghesi M; Ambrosini V; Zanoni L; Gentile G; Vagnoni V; Romagnoli D; Martorana G; Fanti S
    Clin Genitourin Cancer; 2014 Apr; 12(2):106-10. PubMed ID: 24135632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.